Skip to main content

Table 3 British Columbia Randomized Radiation trial, 2005 update

From: Radiation impact in breast cancer

 

Hazard ratio

95% confidence interval

DFS

   All patients

0.63

0.47 to 0.83

   N1 to N3

0.64

0.42 to 0.97

   N4+

0.59

0.38 to 0.91

SysDFS

   All patients

0.66

0.49 to 0.88

   N1 to N3

0.68

0.45 to 1.04

   N4+

0.63

0.41 to 0.97

Overall survival

   All patients

0.73

0.55 to 0.98

   N1 to N3

0.76

0.50 to 1.15

   N4+

0.63

0.41 to 0.97

  1. Cyclophosphamide methotrexate, 5-fluoracil + radiation versus cyclophosphamide methotrexate, 5-fluoracil alone, including all patients and involving patients with one to three axillary nodes involved (N1 to N3) and patients with four or more axillary nodes involved (N4+). DFS, first event breast cancer recurrence (or any death); SysDFS, DFS with systemic recurrence as a first event. Adapted from Ragaz and colleagues [12].